Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Even though Pfizer Inc.'s ( NYSE:PFE ) recent earnings release was robust, the market didn't seem to notice. We ...

LM Real Estate Partners of New York sold Lightstone the property — the firm paid $9 million for it in 2019. The combined ...

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in ...

Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...